NEW YORK, October 20, 2016 /PRNewswire/ --
Stock-Callers.com is focused on the global Generic Drugs industry, whichis expected to grow at a CAGR of 10.53% from 2016 to 2020. Influencing market growth are the outsourcing of drug development and the patent expiry of top-selling branded drugs. Equities under evaluation today: are Akorn Inc. (NASDAQ: AKRX), Eagle Pharmaceuticals
On Wednesday, shares in Lake Forest, Illinois headquartered Akorn Inc. recorded a trading volume of 1.04 million shares. The stock ended the day at $27.73, up 3.12%. The Company's shares are trading below their 200-day moving average by 0.33%. Furthermore, shares of Akorn, which develops, manufactures, and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter consumer health products and animal health pharmaceuticals in the US and internationally, have a Relative Strength Index (RSI) of 49.83.
On October 13th, 2016, Akorn announced that it plans to issue a press release on November 3[rd], 2016, outlining its Q3 2016 results. In addition, the company will host a conference call at 10:00 am EDT on the same day to discuss the financial results. Your complete research report on AKRX can be retrieved for free at:
Woodcliff Lake, New Jersey headquartered Eagle Pharmaceuticals Inc.'s stock finished yesterday's session 0.81% higher at $65.60 and with a total trading volume of 147,941 shares. The Company's shares have gained 1.00% in the last one month and 43.92% over the previous three months. The stock is trading above its 50-day and 200-day moving averages by 4.13% and 21.69%, respectively. Furthermore, shares of Eagle Pharma, which focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the US, have an RSI of 52.50. EGRX free report is just a click away at:
At the closing bell on Wednesday, shares in Watertown, Massachusetts headquartered Tetraphase Pharmaceuticals Inc. rose 2.00%, ending the day at $3.57. The stock recorded a trading volume of 444,522 shares, which was above its three months average volume of 337,750 shares. The Company's shares are trading 6.41% below their 50-day moving average. Moreover, shares of Tetraphase Pharma, which develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections, have an RSI of 42.59.
On October 14th, 2016, Tetraphase Pharmaceuticals announced dosing of the first patient in IGNITE4, the company's phase 3 clinical trial evaluating the efficacy and safety of intravenous eravacycline compared to meropenem in complicated intra-abdominal infections. Eravacycline is a novel antibiotic candidate with potent activity against multidrug-resistant pathogens, including carbapenem-resistant enterobacteriaceae, Acinetobacter baumannii, and colistin-resistant bacteria carrying the mcr-1 gene, that is being developed for the treatment of serious and life-threatening bacterial infections. Sign up for your complimentary research report on TTPH at:
Exton, Pennsylvania-based Fibrocell Science Inc.'s stock ended the day 5.23% higher at $0.67 and with a total trading volume of 110,951 shares. Shares of the Company, which focuses on discovering and developing therapies for diseases affecting the skin, connective tissues, and joints in the US, are trading 20.12% below their 50-day moving average. The stock has an RSI of 42.54.
As per notes filed with SEC, on October 5th, 2016, Fibrocell Science received notice from the NASDAQ Stock Market LLC that the company is not in compliance with NASDAQ Listing Rule 5550(a)(2), as the minimum bid price of the Company's common stock has been below $1.00 per share for 30 consecutive business days. In accordance with NASDAQ Listing Rule 5810(c)(3)(A), the company has a period of 180 calendar days, or until April 3rd, 2017, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company's common stock must meet or exceed $1.00 per share for at least ten consecutive business days during this 180 calendar day period. Register for free on Stock-Callers.com and download the latest research report on FCSC at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Sedentary lifestyle is one that has very little or no physical activity at all, whether at work or ...
Ovarian cancer refers to cancer of ovaries. It is called the "Silent killer", as it is difficult to ...
Schizoaffective disorder is a serious mental disorder in which the individual reflects symptoms ...View All